INSM Stock Overview
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Insmed Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$65.63 |
| 52 Week High | US$84.91 |
| 52 Week Low | US$21.92 |
| Beta | 0.84 |
| 1 Month Change | 1.02% |
| 3 Month Change | -17.91% |
| 1 Year Change | 148.79% |
| 3 Year Change | 281.79% |
| 5 Year Change | 176.10% |
| Change since IPO | -60.22% |
Recent News & Updates
Here's Why Insmed Incorporated's (NASDAQ:INSM) CEO May Have Their Pay Bumped Up
May 08
Insmed: Poised For Transformation Beyond ARIKAYCE
Apr 25Insmed Incorporated's (NASDAQ:INSM) Business Is Yet to Catch Up With Its Share Price
Apr 15Recent updates
Here's Why Insmed Incorporated's (NASDAQ:INSM) CEO May Have Their Pay Bumped Up
May 08Insmed: Poised For Transformation Beyond ARIKAYCE
Apr 25Insmed Incorporated's (NASDAQ:INSM) Business Is Yet to Catch Up With Its Share Price
Apr 15
Brensocatib's 2025 Launch Will Transform Bronchiectasis Care
Mar 19 Anticipated U.S. and international launches of brensocatib are key catalysts for significant revenue growth and new market penetration.Insmed: Priority Review For Brensocatib Cements (Limited) Upside Opportunity
Feb 07Is Insmed (NASDAQ:INSM) Using Debt Sensibly?
Jan 20Some Shareholders Feeling Restless Over Insmed Incorporated's (NASDAQ:INSM) P/S Ratio
Dec 24Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data
Nov 20Insmed Incorporated's (NASDAQ:INSM) Share Price Not Quite Adding Up
Sep 12Insmed: Brensocatib Propels Stock As Regulatory Milestones Approach
Aug 28Is Insmed (NASDAQ:INSM) A Risky Investment?
Aug 10Insmed Incorporated's (NASDAQ:INSM) 92% Share Price Surge Not Quite Adding Up
May 29Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)
May 28Shareholder Returns
| INSM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.7% | -6.1% | 1.3% |
| 1Y | 148.8% | -13.2% | 8.2% |
Return vs Industry: INSM exceeded the US Biotechs industry which returned -13.5% over the past year.
Return vs Market: INSM exceeded the US Market which returned 7.7% over the past year.
Price Volatility
| INSM volatility | |
|---|---|
| INSM Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: INSM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: INSM's weekly volatility has decreased from 18% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 1,271 | Will Lewis | www.insmed.com |
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa.
Insmed Incorporated Fundamentals Summary
| INSM fundamental statistics | |
|---|---|
| Market cap | US$12.41b |
| Earnings (TTM) | -US$913.77m |
| Revenue (TTM) | US$363.71m |
32.8x
P/S Ratio-13.1x
P/E RatioIs INSM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INSM income statement (TTM) | |
|---|---|
| Revenue | US$363.71m |
| Cost of Revenue | US$85.74m |
| Gross Profit | US$277.97m |
| Other Expenses | US$1.19b |
| Earnings | -US$913.77m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.03 |
| Gross Margin | 76.43% |
| Net Profit Margin | -251.24% |
| Debt/Equity Ratio | 443.1% |
How did INSM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/08 06:57 |
| End of Day Share Price | 2025/05/08 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Insmed Incorporated is covered by 34 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neena Bitritto-Garg | Baird |
| Anita Dushyanth | Berenberg |
| Jason Zemansky | BofA Global Research |